Microfluidizer Processors for Pharmaceuticals


Microfluidizer processors enable researchers to accomplish the previously impossible, such as the development of innovative methods for targeted drug delivery using multi-functional nanomedicine.
More than 1,100 pharmaceutical companies — including 19 of the top 20 — rely on Microfluidization technology as the undisputed gold standard for uniform particle size reduction for nanoemulsions, dispersions, nanoencapsulation and cell disruption. Customers such as Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Wyeth have all published the use of our dedicated pharmaceutical homogenizers/processors to develop and produce well-known drugs and vaccines on the market today.

From startups to contract manufacturers to global pharma, nearly two-thirds of the more than 3,000 Microfluidizer processors installed worldwide are used for biopharmaceutical applications. By reducing particle size uniformly, we help pharma leaders improve the quality, bioavailability, stability and process efficiency of their drugs.


Proven Process Efficiency


From startups to contract manufacturers to global pharma, nearly two-thirds of the more than 3,000 Microfluidizer processors installed worldwide are used for biopharmaceutical applications. By reducing particle size uniformly, we help pharma leaders improve the quality, bioavailability, stability and process efficiency of their drugs.


Pharmaceutical

Microfluidizer processors enable researchers to accomplish the previously impossible, such as the development of innovative methods for targeted drug delivery using multi-functional nanomedicine.

  • Vaccines/adjuvants
  • Cancer therapeutics
  • Antibiotics
  • Injectables
  • Inhalables
  • Liposomes
  • Anesthetics
  • Steroids
  • Drug nanosuspensions
  • High shear particle size reduction
  • Uniform particle size distribution
  • Guaranteed scaleup
  • Biopharma-grade models available
  • Continuous crystallization
  • Steam-in-Place capabilities
  • cGMP/21 CFR Part 11 compliance
  • 50% smaller particles than conventional homogenizers
  • Improved bioavailability
  • Enhanced stability for extended shelf life
  • Targeted drug delivery
  • Sterile filtration (< 200 nm)
  • Less filter material required
  • Minimized or eliminated contamination

Tab three content - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. 

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. 

Pharmaceutical Manufacturing and Service Support

Pharmaceutical applications are our main focus. Microfluidics has more than 25 years of experience working with pharmaceutical companies and understands their specific requirements. In addition to manufacturing premium equipment specifically designed for high-end and complex APIs, we offer value-added services to support your success:

  • Factory and on-site acceptance testing (FAT and SAT)
  • Installation Qualification/Operational Qualification (IQ/OQ)
  • Startup and maintenance training
  • Process development consulting
  • Preventive maintenance
  • Scaleup consulting
下载资源:

相关资源/应用

关注我们    
MWu1@idexcorp.com
2022中国国际制药机械博览会秋季展
展位号:S16馆,S16-10
时间:2022.10.15-17
天津国家会展中心
天津市津南区咸水沽镇国展大道888号
返回顶部